HER-CARE Hereditary and Early onset breast cancer: Comprehensive personalized Assessment, early Risk Evaluation, and clinical management
- Coordinator
- Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis, Netherlands
- Runs
- 1 January 2026 to 31 December 2029
- Status
- Running
- EU funding
- €4.7m
- Total cost
- —
- Partners
- 33 organisations in 13 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101227105
What the project is doing
In the project's own words, from its summary on CORDIS.
Breast cancer is the most frequently diagnosed cancer in women, with European countries having some of the highest age-standardized incident rates of early-onset (< age 50) breast cancer in the world. Yet, our understanding of the genetic and environmental factors triggering the pathophysiology of the disease in young women is still limited. Advancing breast cancer prevention and treatment demands a holistic approach towards an accurate and early tumour detection – strongly linked with better clinical outcomes.
HER-CARE aims to revolutionize the approach to hereditary and early-onset breast cancer through an innovative, interdisciplinary research and training program. The project will address critical gaps in early detection, risk stratification, and clinical management by developing tools that integrate genetic, molecular, and imaging data with state-of-the-art technologies, including artificial intelligence, machine learning, and advanced statistical modelling.
These efforts will uncover: i) new molecular mechanisms and biological targets that can be targeted in hereditary and early-onset breast cancer; ii) better multifactorial risk profiles to enhance prediction accuracy; iii) new minimally invasive tools and assays to detect and intercept breast cancer early. The resulting tools and methodologies will: enhance early detection with accessible, personalized treatment and preventative strategies tailored to young women; ii) improve genetic counselling and clinical management; iii) improve treatment guidelines/ cancer prevention programs; and iv) reduce the high rate of misdiagnoses and overtreatment.
HER-CARE will train the next generation of researchers by equipping 15 Doctoral Candidates with multidisciplinary skills spanning genetics, bioinformatics, molecular biology, cancer epidemiology, biostatistics, and computational science to transform the management of hereditary and early-onset breast cancer.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis | Amsterdam | Netherlands | Coordinator |
| Medizinische Universitaet Wien | Wien | Austria | Participant |
| QIMR Berghofer Medical Research Institute | Herston | Australia | Associatedpartner |
| Sophia Genetics SA | Saint-Sulpice | Switzerland | Associatedpartner |
| Kypriako Idryma Erevnon Gia Ti Myiki Distrofia | Agios Dometios | Cyprus | Participant |
| Stremble Ventures Ltd | Limassol | Cyprus | Associatedpartner |
| Masarykova univerzita | Brno | Czechia | Associatedpartner |
| Klinikum Der Universitaet Zu Koeln | Koeln | Germany | Associatedpartner |
| Siemens Healthineers AG | Forchheim | Germany | Associatedpartner |
| Region Syddanmark | Vejle | Denmark | Participant |
| Syddansk Universitet | Odense M | Denmark | Associatedpartner |
| Consorcio Para La Explotacion Del Centro Nacional De Analisis Genomico | Barcelona | Spain | Participant |
| Universitat De Barcelona | Barcelona | Spain | Associatedpartner |
| Institut Gustave Roussy | Villejuif | France | Participant |
| Universite Paris-Saclay | Gif-Sur-Yvette | France | Associatedpartner |
| Academisch Ziekenhuis Leiden | Leiden | Netherlands | Associatedpartner |
| Evidencio BV | Haaksbergen | Netherlands | Participant |
| Methylomics B.V. | Nootdorp | Netherlands | Associatedpartner |
| Stichting Koningin Wilhelmina Fonds Voor De Nederlandse Kankerbestrijding | Amsterdam | Netherlands | Associatedpartner |
| Stichting Radboud Universitair Medisch Centrum | Nijmegen | Netherlands | Associatedpartner |
| Universiteit Twente | Enschede | Netherlands | Associatedpartner |
| Universiteit Utrecht | Utrecht | Netherlands | Participant |
| Karolinska Institutet | Stockholm | Sweden | Participant |
| Astrazeneca UK Limited | Cambridge | United Kingdom | Associatedpartner |
| Foundation for Genomics & Population Health | Cambridge | United Kingdom | Associatedpartner |
| Institute of Cancer Research: the Royal Cancer Hospital Lbg | London | United Kingdom | Participant |
| Oxford Nanopore Technologies Ltd | Oxford | United Kingdom | Associatedpartner |
| Proteotype Diagnostics Ltd | Cambridge | United Kingdom | Participant |
| The Chancellor Masters and Scholars of the University of Cambridge | Cambridge | United Kingdom | Participant |
| The Chancellor, Masters and Scholars of the University of Oxford | Oxford | United Kingdom | Associatedpartner |
| Johns Hopkins University | Baltimore | United States | Associatedpartner |
| Veracyte, Inc. | South San Francisco | United States | Associatedpartner |
| iCAD, Inc | Nashua | United States | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS